Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza białaczki limfoblastycznej typu CD22-dodatni
- •Pacjenci po przeszczepieniu szpiku kostnego z powodu białaczki limfoblastycznej
- •Badanie przeprowadzane 40-100 dni po przeszczepieniu
- •Pacjenci w pierwszej, drugiej lub trzeciej remisji choroby (czyli bez widocznych komórek białaczki)
- •Pacjenci, którzy nie odpowiadali na wcześniejszą chemioterapię lub choroba wróciła
- •Pacjenci mogą chodzić i opiekować się sobą (wydolność fizyczna poniżej 2 stopnia)
- •Wystarczająca liczba białych ciałek i płytek krwi
- •Zgoda na uczestnictwo w badaniu i możliwość przybycia na wizyty
Simplified criteria — AI translation
Trial details
- Minimum age
- 16 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
The University of Kansas Cancer Center
Westwood, United States
Dana-Farber Cancer Institute
Boston, United States
University of Nebraska Medical Center
Omaha, United States
Memorial Sloan Kettering Cancer Center
New York, United States
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, United States
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, United States
The James Cancer Hospital and Solove Research Institute
Columbus, United States
Trial contact
Leland Metheny, MD
Ron Sobecks, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.